Nkarta, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company that develops and commercializes allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. Founded in 2015 and headquartered in South San Francisco, California, the company leverages its proprietary NK expansion platform and cell engineering technologies, including the NKSTIM cell line for rapid donor-derived NK cell expansion, to create potent, scalable therapies targeting abnormal cells. Its lead product candidate, NKX019, a CD19-targeted chimeric antigen receptor (CAR) NK cell therapy, is in Phase 1 clinical trials for B-cell malignancies such as relapsed or refractory B-cell non-Hodgkin's lymphoma and for autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, antineutrophil cytoplasmic antibody-associated vasculitis, myasthenia gravis, and primary membranous nephropathy; NKX101 targets relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes; NKX170 addresses solid tumors. Nkarta operates primarily in the immuno-oncology and autoimmune disease segments, serving patients with life-threatening conditions through off-the-shelf therapies that eliminate patient-specific manufacturing and enable immediate administration. The company's manufacturing process supports commercial-scale production of hundreds of doses per run with cryopreservation capabilities, positioning it for broader accessibility compared to autologous therapies. Recent developments include the initiation of the Ntrust-1 clinical trial for NKX019 in lupus nephritis with the first patient in screening, IND clearance for an investigator-sponsored trial in myasthenia gravis under Ntrust-2, pipeline expansion to additional autoimmune indications, a $240 million underwritten offering, leadership changes with Nadir Mahmood appointed as President and George Vratsanos joining the board, and a global collaboration with CRISPR Therapeutics announced in early 2025 to develop gene-edited NK cell therapies for cancer. Nkarta maintains a strong cash position of approximately $427 million as of mid-2024, funding operations into late 2027, and continues advancing its pipeline with a focus on demonstrating best-in-class efficacy in autoimmune and oncology settings.
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The $13 Million Company Teaching the Immune System to Hunt Cancer
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of “Hold” by Analysts
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Bolt Biotherapeutics (NASDAQ:BOLT) versus Nkarta (NASDAQ:NKTX) Head to Head Review
Nkarta to Participate in March Investor Conferences
Nkarta, Inc. $NKTX Shares Sold by AWM Investment Company Inc.
Nkarta to Participate in Evercore Healthcare Conference
Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Nkarta to Participate in November Investor Conferences
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta to Participate in a September Investor Conference
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025